More recently, advances are being made using CAR T cells against myeloma-specific antigens such as B cell maturation antigen (BCMA), CD138, NY-ESO-1, and kappa-light chain in addition to CD19. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.